Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Acurx Pharmaceuticals Inc ACXP.OQ reported a quarterly adjusted loss of $1.89​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of three analysts for the quarter was for a loss of $2.27 per share. Wall Street expected results to range from $-2.60 to $-2.00 per share.

• Reported revenue was zero​; analysts expected zero.

• Acurx Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.89​.

• The company reported a quarterly loss of $2.25 million.

• Acurx Pharmaceuticals Inc shares had fallen by 56.1% this quarter and lost 72.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 38.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $130.00, about 96.6% above its last closing price of $4.48

This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)